The 2020 ACLS Guidelines were published in October 2020 [1]. This first of 3 blog posts will focus on vasopressor and non-vasopressor medications during cardiac arrest. Part 2 will focus on specific arrhythmia management and Part 3 will focus on toxicologic interventions.
Summary
There were no major updates for vasopressors and non-vasopressors used during cardiac arrest. The American Heart Association (AHA) published Highlights of the 2020 Guidelines [PDF] as a clear and concise summary. Now that the AHA is releasing focused updates in the 5-year period between guidelines (like this one on lidocaine), fewer major changes likely will be needed when the full guidelines are published.
| Vasopressor | Non-Vasopressor |
|---|---|
| Epinephrine
| Amiodarone or lidocaine
|
| Vasopressin
| Steroids
|
| Calcium
| |
| Sodium bicarbonate
| |
| Magnesium
|
Table: Vasopressors and non-vasopressors used during cardiac arrest (VF: ventricular fibrillation, pVT: pulseless ventricular tachycardia)
Reference:
Author information
The post 2020 ACLS Guidelines on Vasopressors and Non-Vasopressors During Cardiac Arrest appeared first on ALiEM.